Autoimmune inflamatory syndrome induced by adjuvants (silicone breast implants and lip fillers)
Abstract
Introduction: Silicone breast implants (SBI) have been used since 1962. in the reconstruction of post-mastectomy cases, in augmentation of the breast, or for cosmetic purposes, and fillers with biopolymer (FB) have been used since the 1990s. Today, they are considered as adjuvants of the immune system. Most complications of SBI and FB are local in nature, but some patients experience systemic symptoms, which is defined as adjuvant-induced autoimmune inflammatory syndrome (ASIA).
Aim: The aim of this study is to demonstrate the possible association of silicone breast implants and FB with the development of immune-mediated inflammatory rheumatic diseases (IMIRD).
Material and methods: The research represent retrospective study which involved 15 women patients with immune-mediated inflammatory rheumatic diseases, 6 of whom were patients with implanted silicone breast implants for cosmetic reasons, and 9 patients with placement of fillers with biopolymer on the lips.
Results: The average time from silicone implantation to the onset of the first symptoms was 6.10 ± 5.3 (range 6 months to 24 years). The following immune-mediated inflammatory rheumatic diseases were recorded: 3 patients with systemic sclerosis (SSc), 3 patients with undifferentiated arthritis, 3 patients with seropositive rheumatoid arthritis, 1 patient with systemic lupus erythematosus, 2 patients with undifferentiated SCTD, 2 patients with mixed connective tissue disease, and one patient with unexplained systemic disease. Seven patients had the Raynaud phenomenon. Spontaneous abortions were reported in 2 patients.
Conclusion: Earlier reports that silicone breast implants and biopolymer fillers are safe today are changing with the description of ASIA syndrome.
References
2. Shoenfeld Y, Agmon-Levin N. ASIA-Autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun. 2011; 36:1-3
3. Hajdu SD, Agmon-Levin N et al. Silicone and autoimmunity. Eur J Clin Invest. 2011; 41(2): 203-211
4. Levy Y, Rotman-Pikielny P et al. Silicone breast implantation-induced scleroderma: description of four patient and critical review of the literature. Lupus. 2009; 18:1226-1232
5. Brawer AE. Amelioration of Systemic Disease after Removal of Silicone Gel-filled Breast Implants. J Nutr Environ Med. 2000; 10:125-132
6. Bekerecioglu M, Onat AM et al. The association between silicone implants and both antibodies and autoimmune disease. Clin Rheumatol. 2008; 27:147-150
7. Greenland S, Finkle WD. A retrospective cohort study of implanted medical devices and selected chronic disease in Medicare claims data. Ann Epidemiol. 2000; 10:205-213
8. Englert H, Joyner E et al. Augmentation mammoplasty and ’silicone-osis’. Int Med J. 2004; 34: 668-676
9. Agmon-Levin N, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies – The result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 2008 8:52-55
10. Maijers MC, de Blok CJ, Niessen FB et al. Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study. Neth J Med. 2013; 71:534-540
11. Vasey FB, Zarabadi SA et al. Where there’s smoke there’s fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol. 2003; 30:2092-2094
12. Vera-Lastra O, Medina G et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld’s syndrome). Lupus. 2012; 21:128-135
13. Cohen Tervaert JW, Kappel RM. Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld’s syndrome). Immunol Res. 2013; 56:293-298
14. Laing TJ, Schottenfeld D et al. Potencial Risk Factors for Undifferentiated Connective Tissue Disease among Women: Implanted Medical Devices. Am J Epidemiol. 2001; 154: 610-617